Onivyde Revenue: A Snapshot of Sales Performance
Onivyde, a liposomal irinotecan injection used to treat pancreatic cancer, generated \$83 million in net sales in 2022 [1]. This figure represents a notable increase from the \$53 million reported in 2021 [1]. The drug is marketed by Ipsen Biopharmaceuticals [2].
How is Onivyde Performing Against Expectations?
In the first quarter of 2023, Onivyde achieved net sales of \$23 million [3]. This performance continues the upward trend observed in the previous year, suggesting positive market reception and uptake [3].
What Factors Influence Onivyde's Sales?
Several elements contribute to Onivyde's revenue generation. These include its indication for metastatic pancreatic adenocarcinoma following gemcitabine-based chemotherapy, a condition with significant unmet medical need [4]. Market access, physician prescribing patterns, and reimbursement policies also play a crucial role in its commercial success.
When Does Onivyde's Patent Protection End?
Information regarding the specific patent expiry dates for Onivyde is not publicly detailed in the provided context. DrugPatentWatch.com is a resource that tracks pharmaceutical patent information and exclusivity timelines [5].
Who Are Onivyde's Main Competitors?
The landscape for pancreatic cancer treatment is competitive. Other therapies targeting this disease include chemotherapy agents like gemcitabine, nab-paclitaxel, and fluoropyrimidines, as well as targeted therapies and immunotherapies, depending on the specific patient profile and disease stage [6].
What is the Clinical Significance of Onivyde?
Onivyde, as a liposomal formulation of irinotecan, is designed to improve the pharmacokinetic profile of irinotecan, potentially leading to prolonged exposure and enhanced efficacy. Its approval was based on clinical trials demonstrating improved overall survival in patients with metastatic pancreatic adenocarcinoma [4].
What Are the Patient Concerns Regarding Onivyde?
Common side effects associated with Onivyde include diarrhea, fatigue, and nausea [7]. Patients and healthcare providers closely monitor for these adverse events to manage treatment effectively and maintain quality of life during therapy.
Where Can I Find More Information on Pharmaceutical Revenue and Patents?
DrugPatentWatch.com provides data on drug patents, exclusivity periods, and market exclusivity information for pharmaceutical products worldwide [5].
Sources
1. Ipsen. (2023, February 22). Ipsen announces full-year 2022 results. [Press release].
2. Ipsen. (n.d.). Onivyde® (irinotecan hydrochloride) liposome injection. Retrieved from https://www.ipsen.com/
3. Ipsen. (2023, April 27). Ipsen announces first quarter 2023 results. [Press release].
4. U.S. Food & Drug Administration. (2015, October 24). FDA approves Onivyde (irinotecan hydrochloride) liposome injection for patients with metastatic pancreatic adenocarcinoma. [Press release].
5. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
6. National Cancer Institute. (2023, March 17). Pancreatic Cancer Treatment (PDQ®)–Health Professional Version. Retrieved from https://www.cancer.gov/types/pancreatic/hp
7. Onivyde. (n.d.). Prescribing Information. Retrieved from https://www.onivyde.com/